The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
ApexOnco Front Page
Recent articles
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
The company is starting four new pivotal trials this year.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
RMC-5127 becomes the company’s fourth clinical project.
